Brief information of the nelfinavir-treated and control groups in clinical trial
DISEASE, COVID-19 INFECTION
To assess the efficacy and safety of nelfinavir in treating patients with mild or moderate COVID-19 infection, we prospectively recruited treatment-naive COVID-19 patients at Shanghai Public Health Clinical Center. The ethical committee of Shanghai Public Health Clinical Center has authorized this study (YJ-2020-E043-02). Between 2020-07-14 and 2021-04-02, out of 44 patients screened, 38 met the criteria for eligibility. Nelfinavir was given to 19 patients, while basic treatment was given to 19 patients, according to randomization. One patient in the control group did not receive the basic treatment after randomization, so 19 and 18 patients were included in FAS/PPS/SS. The age, body weight, sex, ethnic group, disease severity (Supplementary Table S